TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting

Key Takeaways

• PEDD platform shown to increase hepatic tumor penetration in oncopig model
• Clinical data suggest improved embolization outcomes for liver neuroendocrine metastases
• Uterine artery embolization safety and efficacy demonstrated with PEDD device
• TriSalus plans Phase 1 completion and seeks development partnerships

Pulse Analysis

TriSalus Life Sciences is leveraging its proprietary Pressure Enabled Drug Delivery™ (PEDD) technology to address a long‑standing challenge in interventional oncology: getting sufficient drug concentrations into solid tumors while sparing healthy tissue. By modulating pressure and flow during embolization, PEDD promises more uniform distribution of chemotherapeutics and immunotherapies. The upcoming Society of Interventional Radiology meeting provides a high‑visibility platform to demonstrate these capabilities to a specialist audience that directly influences procedural adoption.

At the conference, TriSalus will unveil three distinct data sets. A poster will detail how PEDD improves hepatic tumor penetration in an oncopig model, offering a translational bridge to human liver cancer treatments. A scientific session will compare embolization outcomes for neuroendocrine liver metastases before and after PEDD integration, suggesting measurable efficacy gains. A third session will present safety and efficacy results from uterine artery embolization procedures using a PEDD‑enabled device, expanding the technology’s relevance beyond hepatic applications. Collectively, these findings reinforce the platform’s versatility across multiple organ systems.

Looking ahead, TriSalus is finalizing Phase 1 trials of its TLR‑9 agonist nelitolimod, which is designed to work synergistically with PEDD’s mechanical delivery advantages. Positive trial readouts could unlock partnership discussions with larger pharmaceutical firms seeking to enhance their oncology pipelines. For investors, the convergence of novel delivery mechanics, early clinical validation, and a clear regulatory roadmap signals a potential inflection point that may translate into revenue growth and market differentiation in the competitive interventional oncology space.